These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 27167195

  • 1. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.
    Qi X, Zhao Y, Li H, Guo X, Han G.
    Oncotarget; 2016 Jun 07; 7(23):34703-51. PubMed ID: 27167195
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
    Huang YH, Chen W, Li JP, Chen B, Yang JY.
    Chin Med J (Engl); 2013 Jan 07; 126(2):385-6. PubMed ID: 23324295
    [No Abstract] [Full Text] [Related]

  • 6. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM, STORM investigators.
    Lancet Oncol; 2015 Oct 07; 16(13):1344-54. PubMed ID: 26361969
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
    Bouattour M, Soubrane O, de Gramont A, Faivre S.
    Trials; 2016 Nov 25; 17(1):563. PubMed ID: 27887632
    [Abstract] [Full Text] [Related]

  • 10. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G, SARAH Trial Group.
    Trials; 2014 Dec 03; 15():474. PubMed ID: 25472660
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
    de'Angelis N, Landi F, Carra MC, Azoulay D.
    World J Gastroenterol; 2015 Oct 21; 21(39):11185-98. PubMed ID: 26494973
    [Abstract] [Full Text] [Related]

  • 13. Current management of hepatocellular carcinoma.
    Mendizabal M, Reddy KR.
    Med Clin North Am; 2009 Jul 21; 93(4):885-900, viii. PubMed ID: 19577120
    [Abstract] [Full Text] [Related]

  • 14. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
    Sacco R, Antonucci M, Bargellini I, Marceglia S, Mismas V, Cabibbo G.
    Future Oncol; 2015 Jul 21; 11(17):2371-3. PubMed ID: 26270206
    [No Abstract] [Full Text] [Related]

  • 15. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Geschwind JF, Chapiro J.
    Clin Adv Hematol Oncol; 2016 Aug 21; 14(8):585-7. PubMed ID: 27487101
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.